Broad Institute

<table class="infobox infobox-institution">
<tr><th class="infobox-header" colspan="2">Broad Institute</th></tr>
<tr><td class="infobox-image" colspan="2"><em>Broad Institute Logo</em></td></tr>
<tr><td class="label">Location</td><td>Cambridge, Massachusetts, USA</td></tr>
<tr><td class="label">Type</td><td>Research Institute (Non-profit)</td></tr> [@broadd]
<tr><td class="label">Founded</td><td>2004</td></tr> [@broade]
<tr><td class="label">Website</td><td><a href="https://www.broadinstitute.org/" target="_blank">broadinstitute.org</a></td></tr> [@jonsson2013]
<tr><td class="label">Focus Areas</td><td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis (ALS)](/diseases/als), Human Genetics, Single-Cell Biology, Therapeutics</td></tr> [@sims2017]
<tr><td class="label">Parent Institutions</td><td>[Harvard Medical School](/institutions/harvard-med), [Massachusetts Institute of Technology](/institutions/mit)</td></tr> [@kunkle2019]
</table> [@mathys2019]

Broad Institute

Introduction

The Broad Institute of MIT and Harvard is one of the world's leading biomedical research institutes, founded in 2004 to integrate genomics, computation, chemistry, and clinical science for human disease research[@broad]. Unlike traditional academic departments or medical centers, Broad operates as a collaborative model that brings together the resources and expertise of MIT, Harvard, and major teaching hospitals to accelerate the pace of discovery and translation in human health[@broad].

...

<table class="infobox infobox-institution">
<tr><th class="infobox-header" colspan="2">Broad Institute</th></tr>
<tr><td class="infobox-image" colspan="2"><em>Broad Institute Logo</em></td></tr>
<tr><td class="label">Location</td><td>Cambridge, Massachusetts, USA</td></tr>
<tr><td class="label">Type</td><td>Research Institute (Non-profit)</td></tr> [@broadd]
<tr><td class="label">Founded</td><td>2004</td></tr> [@broade]
<tr><td class="label">Website</td><td><a href="https://www.broadinstitute.org/" target="_blank">broadinstitute.org</a></td></tr> [@jonsson2013]
<tr><td class="label">Focus Areas</td><td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis (ALS)](/diseases/als), Human Genetics, Single-Cell Biology, Therapeutics</td></tr> [@sims2017]
<tr><td class="label">Parent Institutions</td><td>[Harvard Medical School](/institutions/harvard-med), [Massachusetts Institute of Technology](/institutions/mit)</td></tr> [@kunkle2019]
</table> [@mathys2019]

Broad Institute

Introduction

The Broad Institute of MIT and Harvard is one of the world's leading biomedical research institutes, founded in 2004 to integrate genomics, computation, chemistry, and clinical science for human disease research[@broad]. Unlike traditional academic departments or medical centers, Broad operates as a collaborative model that brings together the resources and expertise of MIT, Harvard, and major teaching hospitals to accelerate the pace of discovery and translation in human health[@broad].

In the field of neurodegeneration, Broad's contributions span multiple domains: genetic risk discovery through large-scale genome-wide association studies (GWAS) and whole-exome sequencing; functional genomics using CRISPR-based screens in relevant cell models; single-cell and single-nucleus atlases of human brain tissue; and therapeutic target development through chemical biology and early drug discovery platforms[@broada]. This cross-disciplinary approach has positioned Broad as a central node in international neurodegeneration research consortia, including the Alzheimer's Disease Genetics Consortium (ADGC), the International Parkinson's Disease Genomics Consortium (IPDGC), and the Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD)[@broada].

Broad's model is strongly translational: large-scale data generation and computational analyses are linked to perturbation and validation pipelines that prioritize tractable targets for drug discovery and biomarker development. This integrated approach has made Broad an influential partner in international neurodegeneration consortia, providing both data resources and analytical frameworks that inform disease biology and enable trial-ready hypotheses[@broada].

Overview

The Broad Institute of MIT and Harvard is a major biomedical research institute founded in 2004 to integrate genomics, computation, chemistry, and clinical science for human disease research["@broad"]. In neurodegeneration, Broad's work spans risk-gene discovery, functional genomics in human cell models, single-cell atlas generation, and early therapeutic target development across [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [Amyotrophic Lateral Sclerosis (ALS)](/diseases/als)[@broada]. [@habib2017]

Broad's model is strongly translational: large-scale data generation and computational analyses are linked to perturbation and validation pipelines that prioritize tractable targets for drug discovery and biomarker development. This has made Broad an influential partner in international neurodegeneration consortia, including genetics and multi-omics efforts that inform disease biology and trial-ready hypotheses.

Institutional Structure and Mission

Broad Institute operates as a research institute with multiple integrated programs:

| Component | Focus |
|-----------|-------|
| Genome Sequencing Platform | High-throughput sequencing for population studies[@broadf] |
| Data Sciences Platform | Cloud-based analytics and machine learning[@broadg] |
| Klarman Cell Observatory | Single-cell technologies and cell atlases[@broadd] |
| Chemical Biology Program | Small molecule probes and drug discovery[@broade] |
| Stanley Center | Psychiatric genetics and neuroscience[@broadb] |

The institute receives funding from the National Institutes of Health (NIH), the Howard Hughes Medical Institute (HHMI), private foundations, and pharmaceutical partnerships. This diversified funding model supports both fundamental discovery and translational projects.

Neurodegeneration Research Programs

Brain Health Program

The Broad Brain Health portfolio organizes neuroscience and neurodegeneration work across genetics, molecular profiling, and translational biology[@broada]. Current priorities include:

• Understanding cell-state changes in vulnerable neuronal and glial populations
• Identifying protective variants through human genetics
• Linking molecular signatures to clinical phenotypes and disease progression
• Developing computational frameworks for target prioritization

The Brain Health program leverages Broad's expertise in human genetics, single-cell biology, and chemical biology to address key gaps in understanding neurodegenerative disease mechanisms[@broada]. A core focus is the integration of genetic findings with functional validation to move from association to mechanism.

Stanley Center for Psychiatric Research

The Stanley Center for Psychiatric Research contributes human genetics, statistical genomics, and disease biology platforms that overlap with neurodegenerative research[@broadb]. While primarily focused on schizophrenia, bipolar disorder, and autism, the Stanley Center's work on microglial biology, synaptic function, and innate immune pathways has significant relevance to:

• Alzheimer's disease: Shared microglial activation pathways and complement system involvement
• Parkinson's disease: Neuroinflammation and protein clearance mechanisms
• ALS-FTD spectrum: Common TDP-43 pathology and RNA metabolism defects

The Stanley Center's statistical genetics methods, originally developed for psychiatric disorders, have been adapted for neurodegenerative disease genetics, particularly in the analysis of rare variants and gene-based tests[@broadb].

Medical and Population Genetics Program

The Medical and Population Genetics (MPG) program provides the analytical infrastructure for large-scale genetic studies across neurodegenerative diseases[@broadc]. Key capabilities include:

• GWAS meta-analysis: Combining data across cohorts to identify novel risk loci
• Fine-mapping: Causal variant identification using statistical and functional approaches
• Polygenic risk scoring: Predicting disease risk and progression using genome-wide signals
• Translational genetics: Connecting genetic findings to biological mechanisms and therapeutic targets

MPG investigators have led meta-analyses identifying dozens of novel Alzheimer's and Parkinson's disease risk loci, substantially expanding the understanding of disease architecture[@kunkle2019][@blauwendraat2020].

Klarman Cell Observatory

The Klarman Cell Observatory focuses on comprehensive cell atlases using single-cell genomics technologies[@broadd]. For neurodegeneration, this includes:

• Brain cell atlases: Mapping all cell types in human brain tissue across regions and disease states
• Microglial specialization: Understanding the diversity of immune cells in the aging brain
• Neuronal vulnerability: Identifying why specific neuronal populations are selectively vulnerable
• Glial transitions: Characterizing astrocyte and oligodendrocyte changes in disease

The observatory's work has produced foundational datasets describing the cellular landscape of Alzheimer's and Parkinson's disease brain[@mathys2019][@mathys2024][@bati2024].

Chemical Biology and Therapeutics Science

The Chemical Biology program enables target validation and early drug discovery[@broade]. Capabilities include:

• Targeted small molecules: Chemical probes for protein function studies
• High-throughput screening: Cell-based assays for therapeutic candidate identification
• Medicinal chemistry: Optimization of leads for potency and drug-like properties
• Probe development: Chemical tools for understudied proteins

This infrastructure supports the translation of genetic findings into validated therapeutic targets[@broade].

Representative Scientific Contributions

Human Genetics of Alzheimer's Disease

Broad-affiliated and Broad-collaborative studies helped establish the modern landscape of late-onset Alzheimer's risk genetics. A seminal study identified rare [TREM2](/proteins/trem2-protein) coding variation associated with substantially increased disease risk[@jonsson2013]. This finding, replicated in multiple cohorts, established microglial biology as central to Alzheimer's pathogenesis and ignited a wave of research into TREM2 signaling, CSF sampling, and therapeutic targeting.

Subsequent sequencing analyses implicated immune-related loci including [PLCG2](/proteins/plcg2-protein) and reinforced the role of microglial biology in disease pathogenesis[@sims2017]. The PLCG2 association, involving a phospholipase C enzyme expressed primarily in immune cells, further implicated innate immune signaling in Alzheimer's risk.

Large meta-analyses then expanded risk loci to over 40 genomic regions and converged on pathways involving [Amyloid-Beta](/proteins/amyloid-beta), [tau](/proteins/tau) protein](/proteins/tau), immunity, and lipid biology[@kunkle2019]. The meta-analysis, involving over 35,000 Alzheimer's cases and 45,000 controls, identified both common variants with small effect sizes and rare variants with larger effects, providing a comprehensive picture of genetic architecture.

More recent work has refined the genetic landscape with improved statistical methods and larger sample sizes, identifying additional loci and improving fine-mapping resolution[@bellenguez2022][@schwartzentruber2021]. Polygenic risk scores derived from these findings show predictive utility for identifying at-risk individuals and may eventually inform clinical risk stratification[@wightman2021].

Human Genetics of Parkinson's Disease

Broad investigators have also made substantial contributions to Parkinson's disease genetics. The work has identified risk loci through GWAS, characterized the genetic architecture of diverse populations, and explored the intersection between Alzheimer's and Parkinson's genetics[@blauwendraat2020][@k看不懂2023].

Key findings include:

• LRRK2: Common and rare variants affecting disease risk and progression
• GBA1: Glucocerebrosidase variants as major risk factors, particularly relevant to Lewy body pathology
• SNCA: Alpha-synuclein regulatory variants affecting expression and aggregation propensity
• Multiple new loci: Genes involved in lysosomal function, protein trafficking, and neuroinflammation

The integration of Parkinson's genetics with functional studies has accelerated target validation, particularly for LRRK2 kinase inhibitors which are now in clinical development[@blauwendraat2020].

Genetics of Atypical Parkinsonian Syndromes

Beyond typical Parkinson's disease, Broad has contributed to the genetics of progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA)[@chen2023]. These tauopathies share genetic risk factors with Alzheimer's disease (MAPT, APOE) but also have distinct genetic architectures. Understanding the shared and unique genetic factors may illuminate the basis for selective tau aggregation in different brain regions.

Single-Cell and Multi-Region Atlas Work

Single-cell transcriptomic programs involving Broad investigators have mapped cell-type-specific changes in Alzheimer pathology and cognitive resilience, moving beyond bulk tissue averages[@mathys2019]. Key findings include:

• Microglial states: Multiple distinct microglial populations in AD brain, including disease-associated microglia (DAM) and aging-related microglia
• Neuronal vulnerability: Selective loss of specific excitatory and inhibitory neuronal populations
• Glial reactivity: Astrocyte and oligodendrocyte transcriptional changes reflecting diverse response patterns
• Resilience factors: Gene expression patterns associated with cognitive preservation despite pathological burden

Recent large-scale multiregion analyses identified selective neuronal vulnerability and glial state transitions across affected cortical and subcortical territories[@mathys2024]. This work, analyzing over 1 million nuclei from multiple brain regions, revealed that vulnerability is not uniform across brain regions or cell types, with some neuronal populations showing early dysfunction while others remain relatively protected.

These datasets are increasingly used for therapeutic target nomination, biomarker discovery, and stratification hypotheses for precision trial design. The accessibility of these data through the Broad's Data Sciences Platform has enabled broad community use[@broadg].

Proteomics and Multi-Omics Integration

Beyond genetics and transcriptomics, Broad investigators have led proteomic studies of Alzheimer's disease brain tissue. These studies reveal disease-associated changes in protein abundance, post-translational modifications, and protein network organization[@zhao2023]. Key findings include:

• Signature proteins: Consistent changes in synaptic, mitochondrial, and immune-related proteins
• Module analysis: Co-expression modules identifying disease-related molecular pathways
• Biofluid parallels: CSF and brain tissue protein changes showing partial overlap

Multi-omics integration approaches combine genetic, transcriptomic, proteomic, and epigenetic data to build comprehensive models of disease progression[@zhou2024]. These integrated models identify subtypes, predict progression, and suggest intervention points.

Methods Innovation with Direct Relevance to Brain Tissue

Broad also contributed key enabling methods for single-nucleus profiling, including DroNc-seq, which expanded scalable molecular analysis of archived human brain tissue[@habib2017]. This method enables analysis of frozen tissue, dramatically expanding the range of samples that can be studied. Key applications include:

• Retrospective studies: Using banked tissue from well-characterized cohorts
• Multi-center integration: Harmonizing data across different brain banks
• Temporal analysis: Studying tissue from different disease stages

These methodological advances accelerated cross-cohort integration and improved reproducibility for aging and dementia studies.

Microglia and Innate Immunity Research

A major focus at Broad is understanding the role of microglia in neurodegeneration. This work spans:

Genetic studies: Identifying microglia-expressed genes associated with AD risk (TREM2, PLCG2, ABI3, etc.)[@jonsson2013][@sims2017]

Functional studies: Using iPSC-derived microglia and CRISPR screens to understand gene function[@he2024][@park2024]

Single-cell characterization: Mapping microglial diversity in AD and PD brain[@gupta2023][@yang2023]

Therapeutic targeting: Developing approaches to modulate microglial function for neuroprotection

This work positions Broad as a leader in understanding how innate immunity contributes to neurodegeneration and how it might be therapeutically modulated.

ALS and Frontotemporal Dementia Genetics

Broad has also contributed to the genetics of ALS and the ALS-FTD spectrum[@lopes2022]. Key findings include:

• C9orf72 repeat expansion: The most common genetic cause of familial ALS and FTD
• TARDBP (TDP-43): Coding mutations causing ALS
• FUS: RNA-binding protein mutations in ALS
• Modifying genes: Variation affecting age of onset and disease progression

The overlap between ALS and FTD genetics, involving TDP-43 pathology, has been a productive area of investigation[@tayton2023].

Target Identification and Prioritization

Beyond discovery, Broad has developed computational and experimental approaches for target identification:

• Human genetics prioritization: Using GWAS and exome sequencing to identify likely causal genes[@liu2023]
• CRISPR functional validation: Systematic testing of candidate genes in relevant cell models[@he2024]
• Machine learning integration: Combining multiple data types to predict therapeutic targets[@srivastava2024]
• Multi-omics network analysis: Understanding gene function in the context of protein interaction networks

These approaches accelerate the translation from genetic findings to validated therapeutic targets ready for drug development.

Role in Translational Ecosystems

Broad's contribution to neurodegeneration is less about a single disease clinic and more about shared enabling infrastructure:

• Genetic discovery and interpretation: Variant-to-function pipelines that prioritize actionable biology
• Cellular modeling and perturbation: CRISPR and transcriptomic approaches to test causality in relevant cellular contexts
• Consortium-scale data science: Harmonized analyses that connect cohorts, modalities, and disease stages
• Therapeutic handoff: Early target validation and chemistry support that can feed preclinical programs and eventual trial pipelines

This cross-disease model is especially relevant for mechanistic overlap among [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and the [ALS-FTD Spectrum](/diseases/als-ftd-spectrum), where immune, lysosomal, and proteostasis pathways recur.

Key Partnerships and Consortia

Broad participates in numerous partnerships that amplify its impact:

| Partnership | Role | Disease Focus |
|-------------|------|---------------|
| AMP-AD | Data generation, analysis | Alzheimer's |
| AMP-PD | Biomarker discovery | Parkinson's |
| IPDGC | Genetic discovery | Parkinson's |
| ADGC | Genetic discovery | Alzheimer's |
| GP2 | Genetic discovery | Parkinson's |

These partnerships provide access to large cohorts, enable data sharing, and coordinate analysis efforts across institutions.

Current Challenges and Opportunities

Despite major progress, key translational gaps remain:

Causal assignment: Improving causal assignment in dense loci where multiple genes are co-expressed

Cell-state biomarkers: Defining biomarkers suitable for routine clinical use

Molecular subtypes: Linking molecular subtypes to treatment response

Therapeutic targeting: Moving from target identification to validated therapeutic candidates

Broad's integrated genetics-to-perturbation framework positions it to help close these gaps, especially through joint efforts with academic medical centers such as [Massachusetts General Hospital](/institutions/mass-general) and [Brigham and Women's Hospital](/institutions/brigham-womens), and through data-sharing ecosystems that support replication and external validation.

Future Directions

Looking forward, Broad's neurodegeneration program is positioned to:

• Expand diverse representation: Including more diverse populations in genetic studies
• Advance single-cell technologies: Moving from transcriptomics to multi-omic single-cell profiling
• Integrate clinical data: Linking molecular findings to clinical outcomes and progression
• Enable precision medicine: Supporting genotype-stratified clinical trials and biomarker-driven patient selection

External Links

• [Broad Institute Official Site](https://www.broadinstitute.org/)
• [Broad Brain Health](https://www.broadinstitute.org/brain-health)
• [Stanley Center for Psychiatric Research](https://www.broadinstitute.org/stanley)
• [Program in Medical and Population Genetics](https://www.broadinstitute.org/mpg/)
• [Klarman Cell Observatory](https://www.broadinstitute.org/klarman-cell-observatory)
• [Chemical Biology and Therapeutics Science](https://www.broadinstitute.org/chemical-biology-and-therapeutics-science)

See Also

• [MIT](/institutions/mit)
• [Harvard University](/institutions/harvard-university)
• [Massachusetts General Hospital](/institutions/mass-general)
• [Brigham and Women's Hospital](/institutions/brigham-womens)
• [Alzheimer's Disease Genetics Consortium](/institutions/adgc)
• [AMP-AD](/institutions/amp-ad)
• [AMP-PD](/institutions/amp-pd)
• [TREM2](/proteins/trem2-protein)
• [PLCG2](/proteins/plcg2-protein)
• [Alpha-synuclein](/proteins/alpha-synuclein)

References

[Broad Institute, About Us](https://www.broadinstitute.org/about-us)

[Broad Institute, Brain Health](https://www.broadinstitute.org/brain-health)

[Broad Institute, Stanley Center for Psychiatric Research](https://www.broadinstitute.org/stanley)

[Broad Institute, Medical and Population Genetics Research](https://www.broadinstitute.org/mpg/)

[Broad Institute, Klarman Cell Observatory](https://www.broadinstitute.org/klarman-cell-observatory)

[Broad Institute, Chemical Biology and Therapeutics Science](https://www.broadinstitute.org/chemical-biology-and-therapeutics-science)

[Broad Institute, Genome Sequencing Platform](https://www.broadinstitute.org/scientific-core-resources/genome-sequencing)

[Broad Institute, Data Sciences Platform](https://www.broadinstitute.org/data-sciences-platform)

[Jonsson et al., Variant of TREM2 associated with the risk of Alzheimer's Disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23150908/)

[Sims et al., Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's Disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28714976/)

[Kunkle et al., Genetic meta-analysis of diagnosed Alzheimer's Disease identifies new risk loci and implicates A-beta, tau, immunity and lipid processing (2019)](https://pubmed.ncbi.nlm.nih.gov/30820047/)

[Mathys et al., Single-cell transcriptomic analysis of Alzheimer's Disease (2019)](https://doi.org/10.1038/s41586-019-1195-2)

[Mathys et al., Single-cell multiregion dissection of Alzheimer's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/39048816/)

[Habib et al., Massively parallel single-nucleus RNA-seq with DroNc-seq (2017)](https://pubmed.ncbi.nlm.nih.gov/28846088/)

[Bellenguez et al., New insights into the genetic architecture of Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35061005/)

[Wightman et al., The impact of polygenic risk on Alzheimer's disease incidence (2021)](https://pubmed.ncbi.nlm.nih.gov/34758340/)

[Schwartzentruber et al., Genome-wide meta-analysis, fine-mapping and integrative prioritization in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34594139/)

[Chen et al., Genetic landscape of progressive supranuclear palsy and corticobasal degeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37648270/)

[Kim et al., Genetic architecture of Parkinson's disease in diverse populations (2023)](https://pubmed.ncbi.nlm.nih.gov/37295617/)

[Blauwendraat et al., The genetic landscape of Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32227187/)

[Chen et al., Amyloid, tau and neurodegeneration biomarker measurements in cerebrospinal fluid (2022)](https://pubmed.ncbi.nlm.nih.gov/35088633/)

[Zhao et al., Proteomics of brain tissue from Alzheimer's disease patients reveals disease-associated changes (2023)](https://pubmed.ncbi.nlm.nih.gov/37007054/)

[Bati et al., Single nucleus transcriptomic profiling of brain tissue from Alzheimer's disease donors (2024)](https://pubmed.ncbi.nlm.nih.gov/38750568/)

[Gupta et al., Microglial activation in Alzheimer's disease single-cell data (2023)](https://pubmed.ncbi.nlm.nih.gov/37876756/)

[Lopes et al., Genetic contributions to ALS and FTD (2022)](https://pubmed.ncbi.nlm.nih.gov/35450691/)

[Tayton et al., C9orf72 repeat expansion in neurodegenerative disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37505982/)

[He et al., CRISPR screens identify therapeutic targets in microglia (2024)](https://pubmed.ncbi.nlm.nih.gov/38215674/)

[Yang et al., Human microglial molecular signatures for therapeutic targeting (2023)](https://pubmed.ncbi.nlm.nih.gov/37944612/)

[Srivastava et al., Machine learning approaches to prioritize Alzheimer's disease genes (2024)](https://pubmed.ncbi.nlm.nih.gov/38472286/)

[Zhou et al., Multi-omics integration reveals AD subtypes (2024)](https://pubmed.ncbi.nlm.nih.gov/38392345/)

[Huang et al., Single-cell epigenomics of aging human brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38554012/)

[Liu et al., Target identification for Alzheimer's disease using human genetics (2023)](https://pubmed.ncbi.nlm.nih.gov/37601274/)

[Park et al., iPSC-derived microglia for disease modeling (2024)](https://pubmed.ncbi.nlm.nih.gov/38327655/)